Please sign in to follow a disease.
Liposarcoma
MONDO:0005060A usually painless malignant tumor that arises from adipose tissue. Microscopically, it may contain a spectrum of neoplastic adipocytes ranging from lipoblasts to pleomorphic malignant adipocytes. Morphologic variants include: well differentiated, dedifferentiated, pleomorphic, and myxoid liposarcoma. The metastatic potential is higher in less differentiated tumors.
Also known as: lip sarcoma, liposarcoma, liposarcoma, malignant, sarcoma of lip
2883 clinical trials for this condition and its sub-types, 58 tagged with Liposarcoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Liposarcoma
-
Dedifferentiated liposarcoma 37 trials
-
Myxoid/round cell liposarcoma 13 trials · 18 incl. sub-types
2 sub-types
- Myxoid liposarcoma 15 trials Sub-types →
- Round cell liposarcoma 3 trials
-
Pleomorphic liposarcoma 8 trials
-
Well-differentiated liposarcoma 5 trials
3 sub-types
- Inflammatory liposarcoma 0 trials
- Sclerosing liposarcoma 0 trials
- Spindle cell liposarcoma 0 trials
-
Adult liposarcoma 0 trials
-
Breast liposarcoma 0 trials
-
Cutaneous liposarcoma 0 trials
-
Esophagus liposarcoma 0 trials
-
Fibroblastic liposarcoma 0 trials
-
Gastric liposarcoma 0 trials
-
Intracranial liposarcoma 0 trials
-
Kidney liposarcoma 0 trials
-
Larynx liposarcoma 0 trials
-
Liposarcoma of bone 0 trials
-
Liposarcoma of the ovary 0 trials
1 sub-type
- Ovarian myxoid liposarcoma 0 trials
-
Mediastinum liposarcoma 0 trials
-
Mixed liposarcoma 0 trials
-
Pediatric liposarcoma 0 trials
-
Vulvar liposarcoma 0 trials
-
Can Pre-Surgery chemo boost outcomes in High-Risk Soft-Tissue sarcoma?
Disease control Not yet recruitingThis phase 3 trial compares adding doxorubicin and ifosfamide (AIM chemotherapy) before standard treatment with pembrolizumab, radiation therapy, and surgery versus standard treatment alone in patients with high-risk soft-tissue sarcomas that can be removed by surgery. Participan…
Phase 3 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a new drug boost chemotherapy against rare sarcomas?
Disease control Not yet recruitingThis trial tests whether adding an experimental drug called DT-7012 to standard chemotherapy (doxorubicin) helps people with advanced soft tissue sarcoma, specifically two subtypes: undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. Participants receive either…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a Patient's own immune cells fight advanced sarcoma?
Disease control Not yet recruitingThis phase 2 trial is testing whether lifileucel, a therapy made from a patient's own tumor-infiltrating lymphocytes (immune cells), can shrink tumors in adults with advanced soft tissue sarcoma. Participants will have their tumor removed to create the personalized therapy, then …
Phase 2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New cocktail aims to shrink sarcomas: bevacizumab joins chemo in phase 2 trial
Disease control Not yet recruitingThis phase 2 trial tests whether adding the drug bevacizumab (Onbevzi) to standard chemotherapy (gemcitabine and docetaxel) can shrink tumors better than chemo alone in people with advanced soft tissue sarcoma. About 92 adults who have already had 1-2 prior chemotherapies will be…
Phase 2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Not yet recruitingThis early-stage trial tests a new treatment for adults with solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells that carry a protein called GPC3. The…
Phase 1 • Sponsor: Seattle Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC